Neurocrine Biosciences Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Neurocrine Biosciences (NBIX) Misses Q1 EPS by 5c
May 5, 2021 4:29 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $0.49, $0.05 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $236.6 million versus the consensus estimate of $252.55 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More